Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results

被引：23

作者：

Gallant, Joel E. ^{[1
]}

Koenig, Ellen ^{[2
]}

Andrade-Villanueva, Jaime F. ^{[3
]}

Chetchotisakd, Ploenchan ^{[4
]}

DeJesus, Edwin ^{[5
]}

Antunes, Francisco ^{[6
]}

Arasteh, Keikawus ^{[7
]}

Rizzardini, Giuliano ^{[8
]}

Fehr, Jan ^{[9
]}

Liu, Hui C. ^{[10
]}

Abram, Michael E. ^{[10
]}

Cao, Huyen ^{[10
]}

Szwarcberg, Javier ^{[10
]}

机构：

[1] Southwest CARE Ctr, Santa Fe, NM USA

[2] Inst Dominicano Estudios Virolog, Santo Domingo, Dominican Rep

[3] Hosp Civil Guadalajara, HIV Unit, Guadalajara, Jalisco, Mexico

[4] Khonkaen Univ, Dept Med, Khon Kaen, Thailand

[5] Orlando Immunol Ctr, Orlando, FL USA

[6] Fac Med Lisbon, Inst Saude Ambiental, Lisbon, Portugal

[7] Vivantes Auguste Viktoria Klinikum, EPIMED, Berlin, Germany

[8] Luigi Sacco Hosp, Dept Infect Dis, Milan, Italy

[9] Univ Zurich, Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland

[10] Gilead Sci Inc, Foster City, CA 94404 USA

来源：

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2015年 / 69卷 / 03期

关键词：

Cobicistat; pharmacoenhancer; HIV; Antiretroviral; clinical trial; INITIAL TREATMENT; TREATMENT-NAIVE; DOUBLE-BLIND; LOPINAVIR/RITONAVIR; PHARMACOKINETICS; INFECTION; GS-9350; REGIMEN;

D O I：

10.1097/QAI.0000000000000598

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background:Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity.Methods:International, randomized double-blind active-controlled trial to evaluate the efficacy and safety of COBI vs ritonavir (RTV) as a pharmacoenhancer of atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate in HIV treatment-naive patients followed through week 144.Results:At Week 144, virologic suppression was achieved in 72% (COBI) and 74% (RTV) of patients. Adverse events leading to study drug discontinuation occurred in 11% of patients in each group. Median changes in serum creatinine (mg/dL) were +0.13 (COBI) and +0.07 (RTV) and were unchanged from week 48.Conclusions:Once-daily COBI is a safe and effective pharmacoenhancer of the protease inhibitor atazanavir.

引用

页码：338 / 340

页数：3

共 50 条

[31] Stribild® (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate): A New Paradigm for HIV-1 Treatment
Manzardo, Christian
Gatell, Jose M.
AIDS REVIEWS, 2014, 16 (01) : 35 - 42
[32] Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
Cohen, Calvin
Elion, Richard
Ruane, Peter
Shamblaw, David
DeJesus, Edwin
Rashbaum, Bruce
Chuck, Steven L.
Yale, Kitty
Liu, Hui C.
Warren, David R.
Ramanathan, Srinivasan
Kearney, Brian P.
AIDS, 2011, 25 (06) : F7 - F12
[33] Randomized, Double-blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results
Clumeck, Nathan
Molina, Jean-Michel
Henry, Keith
Gathe, Joseph
Rockstroh, Juergen K.
DeJesus, Edwin
Wei, Xuelian
White, Kirsten
Fordyce, Marshall W.
Rhee, Martin S.
Szwarcberg, Javier
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 65 (03) : E121 - E124
[34] Ritonavir/emtricitabine/tenofovir disoproxil fumarate interactionAcute kidney injury and Fanconi syndrome: case report
Reactions Weekly, 2015, 1553 (1) : 265 - 265
[35] Combination Therapy Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Associated with Hepatic Failure
Qayyum, Sohail
Dong, Huijun
Kovacic, Dianne
Sohail, Sidra
Waters, Bradford
Thornton, Camille
Corbett, Cathy E.
CURRENT DRUG SAFETY, 2012, 7 (05) : 391 - 393
[36] Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results
Arribas, Jose R.
Thompson, Melanie
Sax, Paul E.
Haas, Bernhard
McDonald, Cheryl
Wohl, David A.
DeJesus, Edwin
Clarke, Amanda E.
Guo, Susan
Wang, Hui
Callebaut, Christian
Plummer, Andrew
Cheng, Andrew
Das, Moupali
McCallister, Scott
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 75 (02) : 211 - 218
[37] Severe lactic acidosis during tenofovir disoproxil fumarate and cobicistat combination for HIV patient
Isoda, Atsushi
Mihara, Masahiro
Matsumoto, Morio
Sawamura, Morio
BMJ CASE REPORTS, 2023, 16 (11)
[38] Atazanavir/emtricitabine/tenofovir disoproxil fumarate/ritonavirLiver injury leading to hyperbilirubinaemia and panlobular necrosis: case report
Reactions Weekly, 2013, 1456 (1) : 7 - 7
[39] Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137
Ramanathan, Srinivasan
Shen, Gong
Cheng, Andrew
Kearney, Brian P.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 45 (03) : 274 - 279
[40] Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults
Cohen, Calvin
Wohl, David
Arribas, Jose R.
Henry, Keith
Van Lunzen, Jan
Bloch, Mark
Towner, William
Wilkins, Edmund
Ebrahimi, Ramin
Porter, Danielle
White, Kirsten
Walker, Ivan
Chuck, Susan
De-Oertel, Shampa
Fralich, Todd
AIDS, 2014, 28 (07) : 989 - 997

← 1 2 3 4 5 →